An Aggrephagy-Related LncRNA Signature for the Prognosis of Pancreatic Adenocarcinoma.
Xueyuan HuangHao ChiSiqi GouXiyuan GuoLin LiGaoge PengJinhao ZhangJiayu XuSiji NianQing YuanPublished in: Genes (2023)
Pancreatic adenocarcinoma (PAAD) is a common, highly malignant, and aggressive gastrointestinal tumor. The conventional treatment of PAAD shows poor results, and patients have poor prognosis. The synthesis and degradation of proteins are essential for the occurrence and development of tumors. Aggrephagy is a type of autophagy that selectively degrades aggregated proteins. It decreases the formation of aggregates by degrading proteins, thus reducing the harm to cells. By breaking down proteins, it decreases the formation of aggregates; thus, minimizing damage to cells. For evaluating the response to immunotherapy and prognosis in PAAD patients, in this study, we developed a reliable signature based on aggrephagy-related genes (ARGs). We obtained 298 AGGLncRNAs. Based on the results of one-way Cox and LASSO analyses, the lncRNA signature was constructed. In the risk model, the prognosis of patients in the low-risk group was noticeably better than that of the patients in the high-risk group. Additionally, the ROC curves and nomograms validated the capacity of the risk model to predict the prognosis of PAAD. The patients in the low-risk and high-risk groups showed considerable variations in functional enrichment and immunological analysis. Regarding drug sensitivity, the low-risk and high-risk groups had different half-maximal inhibitory concentrations (IC50).
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- poor prognosis
- prognostic factors
- peritoneal dialysis
- emergency department
- blood pressure
- heart rate
- induced apoptosis
- endoplasmic reticulum stress
- cell death
- high intensity
- patient reported
- smoking cessation
- drug induced
- cell cycle arrest
- resistance training